Important: Compounded tirzepatide discussed in this article is not FDA-approved and has not been evaluated by the FDA for safety or efficacy. This review is for educational purposes only. All prescribing decisions are made by licensed clinicians. Consult your healthcare provider before starting any prescription treatment. Tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Tirzepatide has generated more clinical trial interest than any other weight management medication in the last three years, and search volume for “tirzepatide telehealth” and “compounded tirzepatide” reflects that. MadeMed offers both injectable and oral compounded tirzepatide as part of its GLP-1 weight loss program. This article covers what tirzepatide actually is, what the clinical evidence base supports, how MadeMed's tirzepatide programs are structured and priced, the specific regulatory context around oral tirzepatide formats, and what to verify before enrolling.
What Tirzepatide Is and How It Differs from Semaglutide
Tirzepatide is a dual agonist — a single molecule that acts on two hormone receptor pathways simultaneously. It targets both GLP-1 (glucagon-like peptide-1) receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. Semaglutide, by contrast, acts on GLP-1 receptors only. This dual mechanism underlies tirzepatide's differentiated clinical profile.
GLP-1 receptor agonism suppresses appetite, slows gastric emptying, and supports blood glucose regulation — the same mechanism through which semaglutide works. GIP receptor agonism provides a complementary pathway that influences energy metabolism and may enhance GLP-1's effects on appetite and fat storage. In the SURMOUNT clinical trial program, once-weekly injectable tirzepatide at the 15mg dose produced average weight reduction of approximately 20 to 22 percent in adults with obesity — figures that exceeded the STEP trial results for injectable semaglutide at 2.4mg in comparable populations. These are the results from FDA-approved brand-name injectable tirzepatide (Zepbound) studied in peer-reviewed trials, not results established for compounded tirzepatide formulations.
Tirzepatide is FDA-approved as Mounjaro (for type 2 diabetes management) and Zepbound (for chronic weight management) — both as once-weekly subcutaneous injections. There is no FDA-approved oral tirzepatide product in any format as of the date of this review.
MadeMed Tirzepatide: Program Structure and Verified Pricing
MadeMed offers injectable and oral compounded tirzepatide through the same telehealth model as its semaglutide programs. Prospective patients complete an online medical intake reviewed by a licensed clinician affiliated with Xpedicare, LLC. Prescribing is at the clinician's sole discretion; no prescription is guaranteed. If prescribed, medication is dispensed through AbsoluteRx and shipped directly to the patient.
Based on publicly available pricing verified through independent sources as of April 2026: injectable tirzepatide starts at $189 per month at the 2.5mg starting dose. This price includes L-Carnitine, physician consultation, overnight shipping, and injection supplies. MadeMed Club membership ($149/year) provides a $20 per month discount on tirzepatide programs — the largest per-month discount MadeMed offers across its programs — reflecting the higher base pricing of tirzepatide relative to semaglutide. At the $20/month discount rate, the Club membership pays for itself in approximately 7.5 months for patients on tirzepatide.
For oral tirzepatide: a confirmed starting price was not available in independently verified sources as of this writing. Verify the current pricing, availability, and dose tier structure for oral tirzepatide on mademed.com before enrolling. For context on how MadeMed's tirzepatide pricing compares to competitors: MEDVi lists injectable tirzepatide at $279 for the first month and $399 per month ongoing; the market range for compounded injectable tirzepatide across legitimate platforms runs approximately $189 to $699 per month, depending on platform, dose tier, and what is bundled into the monthly price. For a direct platform comparison, see our MadeMed vs. MEDVi comparison.
The Oral Tirzepatide Question: What Patients Need to Understand
This section is the most important part of this article for any patient considering oral tirzepatide, whether from MadeMed or any telehealth platform.
Tirzepatide is a large peptide molecule. As of the date of this review, Eli Lilly has not brought an FDA-approved oral tirzepatide product to market, and no oral tirzepatide formulation has completed phase 3 human clinical trials demonstrating bioavailability and efficacy through any oral delivery route. The reason is pharmacological: tirzepatide's molecular size and peptide structure make oral absorption exceptionally difficult without specialized delivery technology of the kind Novo Nordisk used in the development of oral semaglutide (Rybelsus/oral Wegovy), and even that technology required a decade of development and specific absorption-enhancing excipients.
What telehealth platforms offering “oral tirzepatide” provide is a compounded sublingual formulation—a tablet or lozenge that dissolves under the tongue, relying on sublingual mucosal absorption rather than gastrointestinal absorption. The theoretical mechanism is sound in principle. But there is no published phase 3 human trial data establishing that compounded sublingual tirzepatide achieves meaningful systemic exposure or produces clinical outcomes comparable to injectable tirzepatide. This is a more significant evidence gap than that for compounded oral semaglutide, because oral semaglutide at least has FDA-approved reference products with established human bioavailability data. No equivalent reference product exists for oral tirzepatide.
This is not a reason to dismiss the format categorically. Clinicians prescribe compounded formulations for reasons that are specific to individual patients, and the prescribing decision belongs to the licensed provider who has reviewed your health history. But patients deserve to understand that “oral tirzepatide” through a telehealth platform is a compounded sublingual formulation without an established human efficacy evidence base, not a pill equivalent of Zepbound.
Tirzepatide Side Effects and Contraindications
The side-effect profile of tirzepatide is well established from the SURMOUNT trial program. The most commonly reported effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These are dose-dependent — most pronounced during the dose-escalation phase, when the body is adjusting to each new dose tier — and typically improve after several weeks at a stable dose. Gradual titration, starting at 2.5mg and increasing in increments based on tolerability, is the standard protocol for managing early side effects.
Serious contraindications include personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). Tirzepatide labeling carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies; the human relevance of this finding is uncertain, but the contraindication is absolute for the populations listed. Tirzepatide is also contraindicated during pregnancy. These contraindications apply to all tirzepatide formulations — branded or compounded, injectable or sublingual. A thorough intake review by a licensed clinician before prescribing is not optional — it's the mechanism that ensures these contraindications are identified and respected.
Tirzepatide vs. Semaglutide: Which Is Right for You?
This is a clinical question, not a content question — and it deserves to be answered by a licensed provider who knows your health history. What we can offer is the factual framework. Tirzepatide's dual mechanism has been associated with greater average weight reduction in clinical trials directly comparing the two agents. That does not mean tirzepatide is better for every individual patient. Semaglutide has a longer safety track record, a larger published evidence base, and lower published starting prices at MadeMed and most other platforms. Individual response to GLP-1 and GIP receptor agonism varies. Some patients respond better to one mechanism than the other. The only way to know is a clinical evaluation followed by a structured trial with appropriate monitoring.
For patients who have already tried semaglutide and not achieved an adequate response, tirzepatide represents a mechanistically distinct alternative worth discussing with a prescribing clinician. For patients new to GLP-1 therapy without a prior treatment history, either agent may be appropriate — the decision belongs to the clinician reviewing your specific case. For our full breakdown of MadeMed's complete program offering across both semaglutide and tirzepatide, see our MadeMed platform review. For the oral format evidence comparison across both molecules, see our oral vs. injectable GLP-1 comparison.
Frequently Asked Questions
How does tirzepatide differ from semaglutide?
Semaglutide is a GLP-1 receptor agonist — it mimics one hormone involved in appetite regulation and blood glucose control. Tirzepatide is a dual agonist that acts on both GLP-1 and GIP receptors. The dual mechanism has been associated with greater average weight reduction in clinical trials comparing the two agents, though individual response varies and both require physician evaluation and ongoing medical supervision.
Is MadeMed's oral tirzepatide FDA-approved?
No. As of the date of this review, no oral tirzepatide product has received FDA approval in any format. The oral tirzepatide available through MadeMed and other telehealth platforms is a compounded sublingual formulation. It is not FDA-approved, has not been evaluated by the FDA for safety or efficacy, and should not be interpreted as equivalent to any FDA-approved injectable tirzepatide product.
How much does MadeMed tirzepatide cost?
Based on published April 2026 pricing, MadeMed lists injectable tirzepatide starting at $189 per month at the 2.5mg starting dose, including L-Carnitine, physician consultation, overnight shipping, and injection supplies. MadeMed Club membership ($149/year) provides a $20 per month discount. Oral tirzepatide starting price was not confirmed in independently verified sources as of this writing — verify current pricing directly on mademed.com before enrolling.
What are the most common side effects of tirzepatide?
The most commonly reported side effects in clinical trial data include nausea, diarrhea, vomiting, and constipation. These are dose-dependent and typically most pronounced during dose escalation, often improving after several weeks at a stable dose. Serious contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. A licensed prescribing clinician should review your full medical history before tirzepatide is prescribed.